Drug Trial Radar · NCT02711956
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Dec 2016
Primary completion
Nov 2019
Study completion Nov 2019
Sponsor
- Lead sponsor
- Zenith EpigeneticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694Drug
EnzalutamideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Dose Escalation: Incidence of Dose-limiting Toxicities (DLT) to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ZEN003694 in Combination With Enzalutamide.Time frame: Cycle 1 (Day 1 thru Day 28)
- For Dose Escalation and Dose Confirmation: Incidence of Treatment-emergent Adverse Events (TEAE) and Treatment-related Serious Adverse Events (SAE)Time frame: Cycle 1 Day 1 to 30 days post last dose
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles Medical Center
Los Angeles, California
University of California San Francisco Medical Center
San Francisco, California
Karmanos Cancer Institute
Detroit, Michigan
Karmanos Cancer Institute
Farmington Hills, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Weill Cornell Medicine - New York Presbyterian
New York, New York
Oregon Health & Science University
Portland, Oregon
Seattle Cancer Care Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.